Advertisement

The new phase of pandemic: Are BA.2.75 and BQ.1 competitive variants? An in silico evaluation

  • Martina Zappa
    Affiliations
    Department of Medicine and Surgery, University of Insubria, Varese, Italy
    Search for articles by this author
  • Paolo Verdecchia
    Affiliations
    Fondazione Umbra Cuore e Ipertensione-ONLUS and Division of Cardiology, Hospital S. Maria della Misericordia, Perugia, Italy
    Search for articles by this author
  • Fabio Angeli
    Correspondence
    Corresponding author at: Department of Medicine and Surgery, University of Insubria, Varese, Department of Medicine and Cardiopulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS Tradate, Via Crotto Roncaccio 16, Tradate VA, Italy.
    Affiliations
    Department of Medicine and Surgery, University of Insubria, Varese, Italy

    Istituti Clinici Scientifici Maugeri, IRCCS Tradate, Italy
    Search for articles by this author
Published:November 07, 2022DOI:https://doi.org/10.1016/j.ejim.2022.11.006
      To the Editor

      Abbreviations:

      SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), EU (European Union), EU/EEA (European Union/European Economic Area), VOC (Variant of Concern), VOI (Variant of Interest), ECDC (European centre for Disease Prevention and Control), RBD (Receptor binding domain), ACE2 (Angiotensin converting enzyme 2), S (Spike), Kd (Dissociation constant), ΔGbinding (Binding affinity)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. SARS-CoV-2 variants of concern as of 27 October 2022. European Centre for Disease Prevention and Control. https://www.ecdceuropaeu/en/covid-19/variants-concern. 2022;Last access, October 29, 2022.

        • Zappa M.
        • Verdecchia P.
        • Angeli F.
        Knowing the new Omicron BA.2.75 variant (’Centaurus’): a simulation study.
        Eur J Intern Med. 2022; 105: 107-108
        • Zappa M.
        • Verdecchia P.
        • Spanevello A.
        • Angeli F.
        Structural evolution of severe acute respiratory syndrome coronavirus 2: implications for adhesivity to angiotensin-converting enzyme 2 receptors and vaccines.
        Eur J Intern Med. 2022; 104: 33-36
        • Zhang H.
        • Penninger J.M.
        • Li Y.
        • Zhong N.
        • Slutsky A.S.
        Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.
        Intensive Care Med. 2020; 46: 586-590
        • Angeli F.
        • Zappa M.
        • Reboldi G.
        • Trapasso M.
        • Cavallini C.
        • Spanevello A.
        • et al.
        The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: one year later.
        Eur J Intern Med. 2021; 93: 28-34
        • Verdecchia P.
        • Cavallini C.
        • Spanevello A.
        • Angeli F.
        The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.
        Eur J Intern Med. 2020; 76: 14-20
        • Kumar R.
        • Murugan N.A.
        • Srivastava V.
        Improved binding affinity of Omicron’s spike protein for the human angiotensin-converting enzyme 2 receptor is the key behind its increased virulence.
        Int J Mol Sci. 2022; : 23
        • Sokal A.
        • Broketa M.
        • Barba-Spaeth G.
        • Meola A.
        • Fernandez I.
        • Fourati S.
        • Azzaoui I.
        • de La Selle A.
        • Vandenberghe A.
        • Roeser A.
        • Bouvier-Alias M.
        • Crickx E.
        • Languille L.
        • Michel M.
        • Godeau B.
        • Gallien S.
        • Melica G.
        • Nguyen Y.
        • Zarrouk V.
        • Canoui-Poitrine F.
        • Noizat-Pirenne F.
        • Megret J.
        • Pawlotsky J.M.
        • Fillatreau S.
        • Simon-Loriere E.
        • Weill J.C.
        • Reynaud C.A.
        • Rey F.A.
        • Bruhns P.
        • Chappert P.
        • Mahevas M.
        Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant.
        Immunity. 2022; 55 (e4): 1096-1104
        • Qu P.
        • Evans J.P.
        • Faraone J.
        • Zheng Y.M.
        • Carlin C.
        • Anghelina M.
        • et al.
        Distinct neutralizing antibody escape of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2.
        bioRxiv. 2022;
      2. Spread of the SARS-CoV-2 Omicron variant sub-lineage BQ.1 in the EU/EEA. European Centre for Disease Prevention and Control. https://www.ecdceuropaeu/en/publications-data/spread-sars-cov-2-omicron-variant-sub-lineage-bq1-eueea. 2022;Last access, October 29, 2022.

        • Hu J.
        • Peng P.
        • Cao X.
        • Wu K.
        • Chen J.
        • Wang K.
        • Tang N.
        • Huang A.L.
        Increased immune escape of the new SARS-CoV-2 variant of concern Omicron.
        Cell Mol Immunol. 2022; 19: 293-295
        • Koyama T.
        • Miyakawa K.
        • Tokumasu R.
        • SJ S.
        • Kudo M.
        • Ryo A.
        Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2.
        Future Microbiol. 2022; 17: 417-424
        • Cheng Y.
        • Ma N.
        • Witt C.
        • Rapp S.
        • Wild P.S.
        • Andreae M.O.
        • Poschl U.
        • Su H
        Face masks effectively limit the probability of SARS-CoV-2 transmission.
        Science. 2021;
        • Angeli F.
        • Reboldi G.
        • Trapasso M.
        • Zappa M.
        • Spanevello A.
        • Verdecchia P.
        COVID-19, vaccines and deficiency of ACE2 and other angiotensinases. Closing the loop on the "Spike effect".
        Eur J Intern Med. 2022;
        • Angeli F.
        • Spanevello A.
        • Reboldi G.
        • Visca D.
        • Verdecchia P.
        SARS-CoV-2 vaccines: lights and shadows.
        Eur J Intern Med. 2021; 88: 1-8